Related Experiment Video

Updated: Aug 15, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Transcription factors and drug resistance

Kimitoshi Kohno1, Takeshi Uchiumi, Ichiro Niina

  • 1Department of Molecular Biology, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Fukuoka 807-8555, Japan. k-kohno@med.uoeh-u.ac.jp

European Journal of Cancer (Oxford, England : 1990)
|October 8, 2005
PubMed

Insights

Drug resistance in cancer chemotherapy is a significant challenge. Transcription factors play a crucial role in the complex gene expression that leads to resistance against anticancer agents like cisplatin.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Intrinsic or acquired resistance to anticancer agents impedes chemotherapy success.
  • Anticancer drugs modulate signal transduction pathways and gene expression, influencing drug resistance.
  • The genomic response to anticancer agents involves complex gene expression regulated by multiple transcription factors.

Purpose of the Study:

  • To review the development of solid tumors and drug-resistant cells.
  • To summarize current knowledge on transcription factors involved in drug resistance.
  • To specifically focus on transcription factors contributing to cisplatin resistance.

Main Methods:

  • Literature review on solid tumor development and drug resistance.
  • Review of studies on gene expression modulation by anticancer agents.
  • Analysis of research on transcription factors in drug resistance, particularly cisplatin.

Main Results:

  • Solid tumors develop complex mechanisms of drug resistance.
  • Multiple transcription factors are implicated in the intricate gene expression patterns conferring drug resistance.
  • Transcription factors are key regulators in the development of resistance to chemotherapy drugs like cisplatin.

Conclusions:

  • Transcription factors are critical mediators of anticancer drug resistance.
  • Understanding these transcription factors is essential for overcoming chemotherapy limitations.
  • Targeting transcription factors may offer novel strategies to combat drug-resistant cancers.

More Related Videos

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Transcription Factors02:16

Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
Transcription Factors02:16

Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
General Transcription Factors01:30

General Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...